CLAIM #2788 · AbbVie Inc (ABBV) · 2026Q1 earnings call · Apr 29, 2026 · due Sep 30, 2026
“In Parkinson's disease, we remain on track for an approval decision for tavapadon in the third quarter.”
Roopal Thakkar · CFO / EVP R&D
PENDING
graded after results covering Sep 30, 2026 are reported
How to check this claim
Look at: FDA regulatory decision (approval status) for tavapadon in Parkinson's disease
It came true if: FDA approval decision (approval, CRL, or other action) issued on or before 2026-09-30
Where: Company press release / FDA announcement on tavapadon regulatory status
Verify independently
SEC filings for ABBV ↗ · Claim quote is verbatim from the 2026Q1 earnings call.